Delving into the Latest Updates on Mepivacaine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(+-)-1-Methyl-2',6'-pipecoloxylidide, 1-methyl-2',6'-pipecoloxylidide, DL-Mepivacaine

+ [22]

Target

VGSCs

Action

blockers

Mechanism

Voltage-gated sodium channels blockers

Therapeutic Areas

Other Diseases

Active Indication

Anesthesia

Inactive Indication

Brachial Plexus NeuropathiesDiabetic NeuropathiesNeuralgia, Postherpetic+ [1]

Originator Organization-

Active Organization

NISSIN Pharmaceutical Co., Ltd.

Hospira, Inc.Sandoz AG

+ [2]

Inactive Organization

Relmada Therapeutics, Inc.

Shandong Bestcomm Pharmaceutical Co., Ltd.

Eastman Kodak Co.

Drug Highest PhaseApproved

First Approval Date

(01 Jan 1956),

Anesthesia

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC15H23ClN2O

InChIKeyRETIMRUQNCDCQB-UHFFFAOYSA-N

CAS Registry1722-62-9

View All Structures (2)

Persistent postoperative pain is a substantial pain (scores 4-10 using a 0-10 numeric scale) that develops 3 months after surgery.
Persistent postoperative pain can be a problem even in ambulatory surgery. Loco-regional analgesia could prevent the occurrence of this pathology but contradictory results are found in ancient studies.
This study is the first randomized controlled study in children about loco-regional analgesia and persistent postoperative pain in traumatologic orthopedic surgery.
One interventional arm will receive a locoregional analgesia after general anesthesia and before incision. The other arm will only receive systemic analgesia during general anesthesia.
The incidence of persistent postoperative pain at 3, 6 and 12 months will be compared in these two groups.
The goal is to show the decrease of the incidence of the persistent postoperative pain in the group "locoregional analgesia".

Start Date06 Jun 2024

Sponsor / Collaborator

Nantes University Hospital

[+1]

NCT05425979

/ Enrolling by invitationPhase 4IIT

Onset of Sensory Blockade in Ultrasound-Guided Ankle Block with Mepivacaine Versus Bupivacaine: a Randomized Non-Inferiority Clinical Trial

The purpose of this research is to determine if both local anesthetics (mepivacaine and bupivacaine) are similar in their onset of sensory block to assess the efficiency of ultrasound-guided ankle blocks in our practice. Currently it is the standard of care to perform ankles blocks with both mepivacaine and bupivacaine. However, given similarity in their safety profile researchers would like to compare if one is non-inferior to the other in terms of onset time of ankle block.

Start Date11 Mar 2024

Sponsor / Collaborator

Mayo Clinic

NCT06291727

/ RecruitingPhase 4IIT

Mepivacaine Versus Bupivacaine Spinal Anesthesia for Same Day Discharge Following Total Knee Arthroplasty

This study is a prospective, double-blind prospective randomized controlled trial comparing mepivacaine and bupivacaine spinal anesthesia for same-day discharge readiness following a unilateral primary elective TKA procedure.
Study data will be collected during the patient's hospital stay for their TKA procedure, and the primary outcome of same-day discharge readiness will be assessed the day of surgery. Patients will also be contacted at Day 3 post-op to assess for any complications, current level of pain, and pain medication utilization.

Start Date16 Feb 2024

Sponsor / Collaborator

Prisma Health

100 Clinical Results associated with Mepivacaine Hydrochloride

Login to view more data

100 Translational Medicine associated with Mepivacaine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Mepivacaine Hydrochloride

Login to view more data

2,936

Literatures (Medical) associated with Mepivacaine Hydrochloride

01 Mar 2025·Regional Anesthesia & Pain Medicine

Mepivacaine dosing for spinal anesthesia in pediatric orthopedic surgery: a retrospective chart review

Article

Author: Carley, Michelle ; Sheetz, Miriam ; Zhong, Haoyan ; DelPizzo, Kathryn ; Lauzadis, Justas

BackgroundMepivacaine is an intermediate-acting local anesthetic used for spinal anesthesia in adults. Currently, there are no published dosing guidelines for spinal mepivacaine in patients under age 18.AimsThe purpose of this study is to describe the clinically used doses of mepivacaine by weight and age for orthopedic surgery in pediatrics.MethodsWe performed a retrospective chart review of patients aged 0–18 who received mepivacaine for spinal anesthesia from 2016 to 2022. We performed a secondary analysis for patients aged 0–18 who received spinal anesthesia with bupivacaine or chloroprocaine.ResultsThe data extraction yielded 3627 single-shot mepivacaine spinals. Patient age ranged from 5 to 18 years. Median dosage in milligrams/kilograms (mg/kg) of mepivacaine was calculated for each age group. Our analysis revealed that dosage in mg/kg decreased by patient age and began to plateau at age 15. Bupivacaine was the most common single-shot spinal agent in patients under age 10. After age 10, mepivacaine was more common. Chloroprocaine began to be used in patients older than 8 years.ConclusionsWe describe mepivacaine dosage as a function of age and weight in patients younger than 18 years. As age and weight increased, a lower dose of mepivacaine per kg was administered for spinal anesthesia.

01 Feb 2025·Canadian Journal of Anesthesia/Journal canadien d'anesthésie

The anesthetic and recovery profiles of low-dose hypobaric mepivacaine and bupivacaine for spinal anesthesia in total hip and knee arthroplasty: a prospective observational study

Article

Author: Yoshida, Takayuki ; Tan, Joanne M H ; Chin, Ki Jinn ; Abdullah, Sara ; Chowdhury, Jayanta ; Wang, Wendy

PURPOSESame-day mobilization and early hospital discharge is increasingly emphasized following hip and knee arthroplasty. One challenge of spinal anesthesia in this setting is achieving adequate block height while avoiding excessively large local anesthetic doses and prolonged motor and sensory blockade. Using a hypobaric local anesthetic solution is one potential strategy, as its intrathecal distribution can be reliably manipulated by patient positioning to achieve adequate block height independent of dose.METHODSWe conducted a prospective observational study to determine the clinical characteristics of spinal anesthesia with low-dose hypobaric mepivacaine and bupivacaine in patients undergoing hip and knee arthroplasty. Thirty patients scheduled for same-day discharge received 51 mg of hypobaric 1.5% mepivacaine and 30 patients scheduled for inpatient stay received 10 mg of hypobaric 0.33% bupivacaine.RESULTSThe mean (standard deviation) time to achieve sensory blockade at or above L1 and T10 in the operative limb was 5.7 (1.8) and 7.3 (3.3) min with mepivacaine and 6.2 (2.6) and 8.1 (4.8) min with bupivacaine, respectively. Anesthesia was adequate for surgical commencement in all patients regardless of spinal injection level. Four patients required anesthetic supplementation for surgical completion. Sensory block duration at or above T10 and L1 in the operative limb was 97 (27) and 115 (37) min with mepivacaine and 127 (32) and 161 (34) min with bupivacaine, respectively. Motor function returned by 145 (37) and 217 (43) min in mepivacaine and bupivacaine groups, respectively.CONCLUSIONThe anesthetic profiles of low-dose hypobaric mepivacaine and bupivacaine were favorable for fast-track hip and knee arthroplasty with short and predictable operating times.

01 Feb 2025·Chromatographia

Development and Validation of Confirmatory Quantitative and Screening Methods for 63 Prohibited Substances in Horse Urine Using LC–MS/MS

Author: Goktas, Eylem Funda ; Kabil, Erol

Abstract: The number of potentially abused substances in horse racing is very large and it is not easy to analyze the full range.To facilitate the analyses of substances of abuse, a method has been developed for 63 substances in horse urine using liquid chromatog.-tandem mass spectrometry.The developed method has been validated according to the 2021/808/EC and AORC criteria.The horse urine samples were extracted after enzymic hydrolysis via a C8-BCX SPE cartridge with an automated SPE and analyzed by LC-MS/MS.According to the validation study results, the within-laboratory reproducibility CV was no more than 13.9% and the average recoveries ranged from 90.71 to 117.94% for repeatability and reproducibility.The decision limits (CCα) for quant. anal. and detection capabilities (CCβ) for qual. screening were close to the targeted limit for each substance.The results of the present study showed that the method was able to perform quant. analyses of 54 substances and screening analyses of 9 substances (total 63) in horse urine and that the results were valid and applicable.The validated method was successfully applied to five proficiency tests and three suspected samples.

100 Deals associated with Mepivacaine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00738	Mepivacaine Hydrochloride	N01BB03	DB00961

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	-	-	01 Jan 1956

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neurolytic Block	Preclinical	China	Shandong Bestcomm Pharmaceutical Co., Ltd.	10 Jul 2012
Anesthesia	Preclinical	United States	Eastman Kodak Co.	06 Jan 1960
Brachial Plexus Neuropathies	Preclinical	China	Shandong Bestcomm Pharmaceutical Co., Ltd.	-
Diabetic Neuropathies	Preclinical	United States	Relmada Therapeutics, Inc.	-
Neuralgia, Postherpetic	Preclinical	United States	Relmada Therapeutics, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03838874 (CTgov)	Phase 2/3	Osteoarthritis, Hip \| Osteoarthritis, Knee	154	Low-Dose Bupivacaine (Low-Dose Bupivacaine)	gqjlxmstzh(bfrnfdmuqo) = fnlgmvpfee kekbjkfmcu (eycuyqkhrq, mxkxnlzzow - xjpygwwuts) View more	-	12 Aug 2021
				Mepivacaine (Mepivacaine)	gqjlxmstzh(bfrnfdmuqo) = kgjiaavdou kekbjkfmcu (eycuyqkhrq, jeddsmoxpi - bosafdywkg) View more
NCT03948386 (CTgov)	Phase 4	Osteoarthritis, Hip	159	isobaric bupivacaine (Isobaric Bupivacaine)	czbddlaeio(agivvgshgq) = mubteeloln xilemwexzp (rdnxpjsoqg, mwtrwaiqof - wlcohacmtn) View more	-	07 May 2021
				hyperbaric bupivacaine (Hyperbaric Bupivacaine)	czbddlaeio(agivvgshgq) = fifmeqlmrh xilemwexzp (rdnxpjsoqg, ekytzunjep - epyvfuytbg) View more
NCT03063255 (CTgov)	Phase 4	Spasm \| Bladder Cancer	60	Obturator block (Obturator Block)	xnqamshwrr(ovoelotjcn) = nwwwnnzfau rldljvvegc (oqmxoivmrm, smzyrpaxqa - yufgeuxngk) View more	-	24 Mar 2021
				Neuromuscular block (Neuromuscular Block)	xnqamshwrr(ovoelotjcn) = gzvmftvtyd rldljvvegc (oqmxoivmrm, wgcyvcaite - czgvcroqlh) View more
NCT01574807 (CTgov)	Phase 4	Pain	100	Mepivacaine+Lidocaine (Mepivacaine + Lidocaine)	tjebfxcwix(srykttzkna) = eyocnuvhku sagrpkqcyd (gfblobgpoy, clovumjnzh - lmlrwowuht)	-	17 Nov 2020
				Lidocaine (Lidocaine + Lidocaine)	tjebfxcwix(srykttzkna) = xvebpbmtoo sagrpkqcyd (gfblobgpoy, ncmdmaijjj - rmocsucqph)
NCT02584452 (CTgov)	Not Applicable	Pain, Postoperative \| Anterior Cruciate Ligament Injuries	59	adductor canal continuous nerve catheter+Propofol+Mepivacaine+Fentanyl (Continuous Adductor Canal Nerve Catheter)	pnetvfmumd(szzxfzbeac) = peaelnqwvi cfhahpexxe (upefcdnuqi, hduruhemyf - jocdtlftgj) View more	-	18 Nov 2019
				adductor canal nerve block+ropivacaine+Propofol+Mepivacaine+Fentanyl+dexamethasone (Long Acting Single Bolus Adductor Canal Nerve Block)	pnetvfmumd(szzxfzbeac) = pgzyqqwufa cfhahpexxe (upefcdnuqi, qrblznwuce - xjlvavxupi) View more
NCT03390426 (CTgov)	Phase 4	Intraoperative hypertension	31	Perifemoral Injection of Local Anesthetic+Mepivacaine (Mepivacaine Block Group)	uejnhvthpw(htylpeksio) = lafgzbemdb hgchengryb (aowfuatqrk, rdofuldsel - nyjvnhuzwi) View more	-	30 Oct 2019
				Perifemoral Injection of Local Anesthetic+Saline (Saline Sham Group)	uejnhvthpw(htylpeksio) = vefflzmaob hgchengryb (aowfuatqrk, ydlrihrhxe - svaqgnrtsj) View more
NCT02078063 (Pubmed \| Contraception)	Phase 3	Pain, Postoperative	86	Mepivacaine 1% 10mL	fxauiwcvgo(pkgjzfacls) = euggwntmnj hpnuostytw (jpvekhwrhw, 3.1 - 5.8)	-	01 Jun 2019
				0.9% NaCl	fxauiwcvgo(pkgjzfacls) = vbuunutzng hpnuostytw (jpvekhwrhw, 3.3 - 7.5)
NCT02726620 (CTgov)	Not Applicable	Hypotension	22,435	Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group)	qneiskdjss(lsjblsfcig) = hnhfyhgvlz pvwvssvblp (lotyzfulzp, gcdsgtamll - shlxlgynxn) View more	-	16 May 2019
				Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support)	qneiskdjss(lsjblsfcig) = pvkihneonj pvwvssvblp (lotyzfulzp, lmktsyttij - wgftsnplsp) View more
AUA2018	Not Applicable	Urinary Bladder Diseases	277	mepivacaine	mcsgplwbqr(kggaitqpui) = dlqqhhksad bxegyhebsw (bwinksyzrp )	-	01 Apr 2018
NCT00825786 (CTgov)	Phase 3	-	103	Ropivacaine+Mepivacaine (Group 1)	xtvbsghvcy(idukjnbxdq) = hqvmqwihca wqejdjzbvh (rzfeosnqsg, vgkxiuklql - iawnxsrptu) View more	-	19 Apr 2017
				Ropivacaine+Mepivacaine (Group 2)	xtvbsghvcy(idukjnbxdq) = urpndljzqg wqejdjzbvh (rzfeosnqsg, kjgstdcjrc - ortbsufwdp) View more